Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors

Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors

Abstract Blood pressure measurements form a critical component of adverse event monitoring for tyrosine kinase inhibitors, but might also serve as a biomarker for dose titrations. This study explored the impact of various sources of within‐individual variation on blood pressure readings to improve m...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	Maddalena Centanni, Abel Thijs, Ingrid Desar, Mats O. Karlsson, Lena E. Friberg
Format:	Article
Sprog:	English
Udgivet:	Wiley 2023-01-01
Serier:	Clinical and Translational Science
Online adgang:	https://doi.org/10.1111/cts.13423

Lignende værker

Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
af: Maddalena Centanni, et al.
Udgivet: (2020-03-01)

Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models
af: Eman I. K. Ibrahim, et al.
Udgivet: (2023-09-01)

Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
af: Sarah Waliany, MD, MS, et al.
Udgivet: (2019-09-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
af: Maria Dimou, et al.
Udgivet: (2014-01-01)

TYROSINE KINASE INHIBITORS AND PREGNANCY
af: Elisabetta Abruzzese, et al.
Udgivet: (2014-04-01)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
af: Nick Verougstraete, et al.
Udgivet: (2022-03-01)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
af: Evan Pisick, et al.
Udgivet: (2004-01-01)

Inhibition of c-Kit by tyrosine kinase inhibitors
af: Allison Galanis, et al.
Udgivet: (2015-03-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
af: G. V. Lukina, et al.
Udgivet: (2015-12-01)

Tyrosine Kinase Inhibitors Target B Lymphocytes
af: Nikki Lyn Esnardo Upfold, et al.
Udgivet: (2023-02-01)

Spheroacanthocytes secondary to novel tyrosine kinase inhibitors
af: Michael Ashby, et al.
Udgivet: (2020-11-01)

Second-generation inhibitors of Bruton tyrosine kinase
af: Jingjing Wu, et al.
Udgivet: (2016-09-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
af: Hor-Yue Tan, et al.
Udgivet: (2018-02-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
af: Lihua Huang, et al.
Udgivet: (2015-09-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
af: Yi-fan Chen, et al.
Udgivet: (2011-12-01)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
af: John J. Ryan, MD
Udgivet: (2016-12-01)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
af: Yu Yao, et al.
Udgivet: (2023-01-01)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
af: Ainun Nizar Masbuchin, et al.
Udgivet: (2022-09-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
af: Xu H, et al.
Udgivet: (2019-07-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
af: Huang JT, et al.
Udgivet: (2022-11-01)

Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
af: Zahra Moradpour, et al.
Udgivet: (2019-01-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
af: Yifan Zhang, et al.
Udgivet: (2024-06-01)

Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
af: Jiangnan Liu, et al.
Udgivet: (2024-03-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
af: Obada Ababneh, et al.
Udgivet: (2022-05-01)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
af: Ahmad Assi, et al.
Udgivet: (2023-12-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
af: Tasia Amelia, et al.
Udgivet: (2022-01-01)

Flavonoids as receptor tyrosine kinase inhibitors in lung cancer
af: Sareshma Sudhesh Dev, et al.
Udgivet: (2023-11-01)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
af: Chi-Hao Hu, et al.
Udgivet: (2023-07-01)

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
af: Ashraf El-Dabh, et al.
Udgivet: (2019-07-01)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
af: Qinlian Jiao, et al.
Udgivet: (2018-02-01)

Tyrosine Kinase Inhibitors - Induced Cutaneous Leukocytoclastic Vasculitis
af: Diogo Alpuim Costa, et al.
Udgivet: (2018-05-01)

Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion
af: Vineet Agrawal, et al.
Udgivet: (2015-02-01)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
af: Toshio Fujino, MD, et al.
Udgivet: (2021-03-01)

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
af: D. Samuel Metibemu, et al.
Udgivet: (2019-12-01)

The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance
af: Eliska Ruzickova, et al.
Udgivet: (2019-10-01)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
af: Sachin Gupta, et al.
Udgivet: (2008-10-01)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
af: Domenico Ribatti
Udgivet: (2010-04-01)

A Review on Newer Tyrosine Kinase Inhibitors and their Uses
af: NITHU M KUMAR, et al.
Udgivet: (2018-08-01)

Resistant Mechanism and Treatment Strategy of Tyrosine Kinase Inhibitors
af: Jianbing QIAO, et al.
Udgivet: (2011-10-01)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
af: C. I. Edvard Smith, et al.
Udgivet: (2021-11-01)